Neuromodulation Devices Comprehensive Study by Type (Internal Neuromodulation, External Neuromodulation), Application (Depression, Parkinsons Disease, Tremor, Others), End Users (Hospitals, Clinics, Home healthcare), Bio Material (Metallic, Polymeric, Ceramic) Players and Region - Europe Market Outlook to 2030

Neuromodulation Devices Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 12.6%  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Neuromodulation Devices
Neuromodulation is a technology which is used for the modulation of the nerve activity. It is used to treat the people who are suffering from such condition such as Parkinsonís disease, psychological disorders, essential tremor, urinary, fecal incontinence, chronic pain, and others. There are a number of forms of neuromodulation such as Spinal Cord Stimulation (SCS), Peripheral Nerve Stimulation (PNS) and Deep Brain Stimulation (DBS). Rising geriatric population in developed countries such as, the U.S., Europe, and Japan in developing countries, the rising incidence of neurological disorders and awareness among people and high prevalence of disease conditions, namely chronic pain and Parkinsonís disease, are some of the major drivers which are propelling the growth of the market.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia-Pacific
UnitValue (USD Million)
CAGR12.6%


The market is fragmented with numerous players focusing on technique and quality of the product due to which the global neuromodulation devices market can witness an upsurge in the forecast period. Analyst at AMA Research estimates that United Kingdom Players will contribute the maximum growth to Europe Neuromodulation Devices market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Medical, Inc. (United States.), LivaNova PLC (United Kingdom), Boston Scientific Corporation (United States),, Aleva Neurotherapeutics SA (United States), Bioness Inc. (United States), EnteroMedics Inc (United States), Nevro Corporation (United States), NeuroPace Inc. (United States), Synapse Biomedical, Inc. (United States) and Neurosigma, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Neuronetics, Inc. (United States), Cyberonics, Inc. (United States), BioControl Medical (Israel),, Accellent (United States), DynaMD (United States) and Soterix Medical, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Europe Neuromodulation Devices market by Type (Internal Neuromodulation and External Neuromodulation), Application (Depression, Parkinsons Disease, Tremor and Others) and Region.



On the basis of geography, the market of Neuromodulation Devices has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023. If we see Market by End Users, the sub-segment i.e. Hospitals will boost the Neuromodulation Devices market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Bio Material , the sub-segment i.e. Metallic will boost the Neuromodulation Devices market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Advancement of Neuromodulation Devices

Market Growth Drivers:
Rising Incidence of Neurological Disorders and Increasing Awareness among People and New Neuromodulation Devices Approval by Regulatory Bodies

Challenges:
High Price of Neuromodulation Devices Products

Restraints:
Lack of Trained Healthcare Professionals and Stringent Approval Policies

Opportunities:
Rising Demand from Emerging Economics Such As India, China and Others and Awareness Regarding Mental Disorders and Increasing Expenditure in the Healthcare Sector

Market Leaders and their expansionary development strategies
On December 2017, the LivaNova PLC (United Kingdom) Company had acquired ImThera Medical, Inc. (United States), which is a privately held company and it is focused on neurostimulation for the treatment of obstructive sleep apnea and On April 2016, the Abbott Laboratories (United States) Company had acquired St. Jude Medical (United States), which manufactures new medical device products across neuromodulation, cardiovascular, vision patient care. This acquisition will benefit increase the diversification of the products, services and long-term prospects
On January 2019, the SpineX Company had launched Non-Invasive neuromodulation Devices in order to improve the quality of lives for the patient. It will benefit the increased product portfolio of the company
On January 2018, as per an article published by the Food and Drug Administration, to determine the most efficient regulatory pathway for bringing a medical device such as Neuromodulation to the United States market.

Key Target Audience
Manufacturers of Neuromodulation Devices, Suppliers of Neuromodulation Devices Parts, Wholesalers, Distributors and Retailers of Neuromodulation Devices, Research and Development (R&D) Companies, Research Organization, Federal Agencies and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Internal Neuromodulation
  • External Neuromodulation
By Application
  • Depression
  • Parkinsons Disease
  • Tremor
  • Others
By End Users
  • Hospitals
  • Clinics
  • Home healthcare

By Bio Material
  • Metallic
  • Polymeric
  • Ceramic

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Incidence of Neurological Disorders and Increasing Awareness among People
      • 3.2.2. New Neuromodulation Devices Approval by Regulatory Bodies
    • 3.3. Market Challenges
      • 3.3.1. High Price of Neuromodulation Devices Products
    • 3.4. Market Trends
      • 3.4.1. Technological Advancement of Neuromodulation Devices
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Europe Neuromodulation Devices, by Type, Application, End Users, Bio Material and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Europe Neuromodulation Devices (Value)
      • 5.2.1. Europe Neuromodulation Devices by: Type (Value)
        • 5.2.1.1. Internal Neuromodulation
        • 5.2.1.2. External Neuromodulation
      • 5.2.2. Europe Neuromodulation Devices by: Application (Value)
        • 5.2.2.1. Depression
        • 5.2.2.2. Parkinsons Disease
        • 5.2.2.3. Tremor
        • 5.2.2.4. Others
      • 5.2.3. Europe Neuromodulation Devices by: End Users (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Home healthcare
      • 5.2.4. Europe Neuromodulation Devices Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Europe Neuromodulation Devices (Volume)
      • 5.3.1. Europe Neuromodulation Devices by: Type (Volume)
        • 5.3.1.1. Internal Neuromodulation
        • 5.3.1.2. External Neuromodulation
      • 5.3.2. Europe Neuromodulation Devices by: Application (Volume)
        • 5.3.2.1. Depression
        • 5.3.2.2. Parkinsons Disease
        • 5.3.2.3. Tremor
        • 5.3.2.4. Others
      • 5.3.3. Europe Neuromodulation Devices by: End Users (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Home healthcare
      • 5.3.4. Europe Neuromodulation Devices Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Europe Neuromodulation Devices (Price)
      • 5.4.1. Europe Neuromodulation Devices by: Type (Price)
  • 6. Neuromodulation Devices: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Medical, Inc. (United States.)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. LivaNova PLC (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Boston Scientific Corporation (United States),
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Aleva Neurotherapeutics SA (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Bioness Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. EnteroMedics Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Nevro Corporation (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. NeuroPace Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Synapse Biomedical, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Neurosigma, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Europe Neuromodulation Devices Sale, by Type, Application, End Users, Bio Material and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Europe Neuromodulation Devices (Value)
      • 7.2.1. Europe Neuromodulation Devices by: Type (Value)
        • 7.2.1.1. Internal Neuromodulation
        • 7.2.1.2. External Neuromodulation
      • 7.2.2. Europe Neuromodulation Devices by: Application (Value)
        • 7.2.2.1. Depression
        • 7.2.2.2. Parkinsons Disease
        • 7.2.2.3. Tremor
        • 7.2.2.4. Others
      • 7.2.3. Europe Neuromodulation Devices by: End Users (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Home healthcare
      • 7.2.4. Europe Neuromodulation Devices Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Europe Neuromodulation Devices (Volume)
      • 7.3.1. Europe Neuromodulation Devices by: Type (Volume)
        • 7.3.1.1. Internal Neuromodulation
        • 7.3.1.2. External Neuromodulation
      • 7.3.2. Europe Neuromodulation Devices by: Application (Volume)
        • 7.3.2.1. Depression
        • 7.3.2.2. Parkinsons Disease
        • 7.3.2.3. Tremor
        • 7.3.2.4. Others
      • 7.3.3. Europe Neuromodulation Devices by: End Users (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Home healthcare
      • 7.3.4. Europe Neuromodulation Devices Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Europe Neuromodulation Devices (Price)
      • 7.4.1. Europe Neuromodulation Devices by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Neuromodulation Devices: by Type(USD Million)
  • Table 2. Neuromodulation Devices Internal Neuromodulation , by Region USD Million (2018-2023)
  • Table 3. Neuromodulation Devices External Neuromodulation , by Region USD Million (2018-2023)
  • Table 4. Neuromodulation Devices: by Application(USD Million)
  • Table 5. Neuromodulation Devices Depression , by Region USD Million (2018-2023)
  • Table 6. Neuromodulation Devices Parkinsons Disease , by Region USD Million (2018-2023)
  • Table 7. Neuromodulation Devices Tremor , by Region USD Million (2018-2023)
  • Table 8. Neuromodulation Devices Others , by Region USD Million (2018-2023)
  • Table 9. Neuromodulation Devices: by End Users(USD Million)
  • Table 10. Neuromodulation Devices Hospitals , by Region USD Million (2018-2023)
  • Table 11. Neuromodulation Devices Clinics , by Region USD Million (2018-2023)
  • Table 12. Neuromodulation Devices Home healthcare , by Region USD Million (2018-2023)
  • Table 13. South America Neuromodulation Devices, by Country USD Million (2018-2023)
  • Table 14. South America Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 15. South America Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 16. South America Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 17. South America Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 18. Brazil Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 19. Brazil Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 20. Brazil Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 21. Brazil Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 22. Argentina Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 23. Argentina Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 24. Argentina Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 25. Argentina Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 26. Rest of South America Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 27. Rest of South America Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 28. Rest of South America Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 29. Rest of South America Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 30. Asia Pacific Neuromodulation Devices, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 32. Asia Pacific Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 33. Asia Pacific Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 34. Asia Pacific Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 35. China Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 36. China Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 37. China Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 38. China Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 39. Japan Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 40. Japan Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 41. Japan Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 42. Japan Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 43. India Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 44. India Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 45. India Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 46. India Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 47. South Korea Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 48. South Korea Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 49. South Korea Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 50. South Korea Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 51. Taiwan Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 52. Taiwan Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 53. Taiwan Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 54. Taiwan Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 55. Australia Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 56. Australia Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 57. Australia Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 58. Australia Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 59. Rest of Asia-Pacific Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 60. Rest of Asia-Pacific Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 63. Europe Neuromodulation Devices, by Country USD Million (2018-2023)
  • Table 64. Europe Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 65. Europe Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 66. Europe Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 67. Europe Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 68. Germany Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 69. Germany Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 70. Germany Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 71. Germany Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 72. France Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 73. France Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 74. France Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 75. France Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 76. Italy Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 77. Italy Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 78. Italy Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 79. Italy Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 80. United Kingdom Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 81. United Kingdom Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 82. United Kingdom Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 83. United Kingdom Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 84. Netherlands Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 85. Netherlands Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 86. Netherlands Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 87. Netherlands Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 88. Rest of Europe Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 89. Rest of Europe Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 90. Rest of Europe Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 91. Rest of Europe Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 92. MEA Neuromodulation Devices, by Country USD Million (2018-2023)
  • Table 93. MEA Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 94. MEA Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 95. MEA Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 96. MEA Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 97. Middle East Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 98. Middle East Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 99. Middle East Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 100. Middle East Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 101. Africa Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 102. Africa Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 103. Africa Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 104. Africa Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 105. North America Neuromodulation Devices, by Country USD Million (2018-2023)
  • Table 106. North America Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 107. North America Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 108. North America Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 109. North America Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 110. United States Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 111. United States Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 112. United States Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 113. United States Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 114. Canada Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 115. Canada Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 116. Canada Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 117. Canada Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 118. Mexico Neuromodulation Devices, by Type USD Million (2018-2023)
  • Table 119. Mexico Neuromodulation Devices, by Application USD Million (2018-2023)
  • Table 120. Mexico Neuromodulation Devices, by End Users USD Million (2018-2023)
  • Table 121. Mexico Neuromodulation Devices, by Bio Material USD Million (2018-2023)
  • Table 122. Neuromodulation Devices Sales: by Type(K Units)
  • Table 123. Neuromodulation Devices Sales Internal Neuromodulation , by Region K Units (2018-2023)
  • Table 124. Neuromodulation Devices Sales External Neuromodulation , by Region K Units (2018-2023)
  • Table 125. Neuromodulation Devices Sales: by Application(K Units)
  • Table 126. Neuromodulation Devices Sales Depression , by Region K Units (2018-2023)
  • Table 127. Neuromodulation Devices Sales Parkinsons Disease , by Region K Units (2018-2023)
  • Table 128. Neuromodulation Devices Sales Tremor , by Region K Units (2018-2023)
  • Table 129. Neuromodulation Devices Sales Others , by Region K Units (2018-2023)
  • Table 130. Neuromodulation Devices Sales: by End Users(K Units)
  • Table 131. Neuromodulation Devices Sales Hospitals , by Region K Units (2018-2023)
  • Table 132. Neuromodulation Devices Sales Clinics , by Region K Units (2018-2023)
  • Table 133. Neuromodulation Devices Sales Home healthcare , by Region K Units (2018-2023)
  • Table 134. South America Neuromodulation Devices Sales, by Country K Units (2018-2023)
  • Table 135. South America Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 136. South America Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 137. South America Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 138. South America Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 139. Brazil Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 140. Brazil Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 141. Brazil Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 142. Brazil Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 143. Argentina Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 144. Argentina Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 145. Argentina Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 146. Argentina Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 147. Rest of South America Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 148. Rest of South America Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 149. Rest of South America Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 150. Rest of South America Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 151. Asia Pacific Neuromodulation Devices Sales, by Country K Units (2018-2023)
  • Table 152. Asia Pacific Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 153. Asia Pacific Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 154. Asia Pacific Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 155. Asia Pacific Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 156. China Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 157. China Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 158. China Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 159. China Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 160. Japan Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 161. Japan Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 162. Japan Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 163. Japan Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 164. India Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 165. India Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 166. India Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 167. India Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 168. South Korea Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 169. South Korea Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 170. South Korea Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 171. South Korea Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 172. Taiwan Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 173. Taiwan Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 174. Taiwan Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 175. Taiwan Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 176. Australia Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 177. Australia Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 178. Australia Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 179. Australia Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 180. Rest of Asia-Pacific Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 181. Rest of Asia-Pacific Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 182. Rest of Asia-Pacific Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 183. Rest of Asia-Pacific Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 184. Europe Neuromodulation Devices Sales, by Country K Units (2018-2023)
  • Table 185. Europe Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 186. Europe Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 187. Europe Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 188. Europe Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 189. Germany Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 190. Germany Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 191. Germany Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 192. Germany Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 193. France Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 194. France Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 195. France Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 196. France Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 197. Italy Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 198. Italy Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 199. Italy Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 200. Italy Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 201. United Kingdom Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 202. United Kingdom Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 203. United Kingdom Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 204. United Kingdom Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 205. Netherlands Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 206. Netherlands Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 207. Netherlands Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 208. Netherlands Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 209. Rest of Europe Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 210. Rest of Europe Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 211. Rest of Europe Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 212. Rest of Europe Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 213. MEA Neuromodulation Devices Sales, by Country K Units (2018-2023)
  • Table 214. MEA Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 215. MEA Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 216. MEA Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 217. MEA Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 218. Middle East Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 219. Middle East Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 220. Middle East Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 221. Middle East Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 222. Africa Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 223. Africa Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 224. Africa Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 225. Africa Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 226. North America Neuromodulation Devices Sales, by Country K Units (2018-2023)
  • Table 227. North America Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 228. North America Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 229. North America Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 230. North America Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 231. United States Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 232. United States Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 233. United States Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 234. United States Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 235. Canada Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 236. Canada Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 237. Canada Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 238. Canada Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 239. Mexico Neuromodulation Devices Sales, by Type K Units (2018-2023)
  • Table 240. Mexico Neuromodulation Devices Sales, by Application K Units (2018-2023)
  • Table 241. Mexico Neuromodulation Devices Sales, by End Users K Units (2018-2023)
  • Table 242. Mexico Neuromodulation Devices Sales, by Bio Material K Units (2018-2023)
  • Table 243. Neuromodulation Devices: by Type(USD/Units)
  • Table 244. Company Basic Information, Sales Area and Its Competitors
  • Table 245. Company Basic Information, Sales Area and Its Competitors
  • Table 246. Company Basic Information, Sales Area and Its Competitors
  • Table 247. Company Basic Information, Sales Area and Its Competitors
  • Table 248. Company Basic Information, Sales Area and Its Competitors
  • Table 249. Company Basic Information, Sales Area and Its Competitors
  • Table 250. Company Basic Information, Sales Area and Its Competitors
  • Table 251. Company Basic Information, Sales Area and Its Competitors
  • Table 252. Company Basic Information, Sales Area and Its Competitors
  • Table 253. Company Basic Information, Sales Area and Its Competitors
  • Table 254. Neuromodulation Devices: by Type(USD Million)
  • Table 255. Neuromodulation Devices Internal Neuromodulation , by Region USD Million (2025-2030)
  • Table 256. Neuromodulation Devices External Neuromodulation , by Region USD Million (2025-2030)
  • Table 257. Neuromodulation Devices: by Application(USD Million)
  • Table 258. Neuromodulation Devices Depression , by Region USD Million (2025-2030)
  • Table 259. Neuromodulation Devices Parkinsons Disease , by Region USD Million (2025-2030)
  • Table 260. Neuromodulation Devices Tremor , by Region USD Million (2025-2030)
  • Table 261. Neuromodulation Devices Others , by Region USD Million (2025-2030)
  • Table 262. Neuromodulation Devices: by End Users(USD Million)
  • Table 263. Neuromodulation Devices Hospitals , by Region USD Million (2025-2030)
  • Table 264. Neuromodulation Devices Clinics , by Region USD Million (2025-2030)
  • Table 265. Neuromodulation Devices Home healthcare , by Region USD Million (2025-2030)
  • Table 266. South America Neuromodulation Devices, by Country USD Million (2025-2030)
  • Table 267. South America Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 268. South America Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 269. South America Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 270. South America Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 271. Brazil Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 272. Brazil Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 273. Brazil Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 274. Brazil Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 275. Argentina Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 276. Argentina Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 277. Argentina Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 278. Argentina Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 279. Rest of South America Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 280. Rest of South America Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 281. Rest of South America Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 282. Rest of South America Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 283. Asia Pacific Neuromodulation Devices, by Country USD Million (2025-2030)
  • Table 284. Asia Pacific Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 285. Asia Pacific Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 286. Asia Pacific Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 287. Asia Pacific Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 288. China Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 289. China Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 290. China Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 291. China Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 292. Japan Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 293. Japan Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 294. Japan Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 295. Japan Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 296. India Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 297. India Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 298. India Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 299. India Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 300. South Korea Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 301. South Korea Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 302. South Korea Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 303. South Korea Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 304. Taiwan Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 305. Taiwan Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 306. Taiwan Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 307. Taiwan Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 308. Australia Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 309. Australia Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 310. Australia Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 311. Australia Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 312. Rest of Asia-Pacific Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 313. Rest of Asia-Pacific Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 314. Rest of Asia-Pacific Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 315. Rest of Asia-Pacific Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 316. Europe Neuromodulation Devices, by Country USD Million (2025-2030)
  • Table 317. Europe Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 318. Europe Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 319. Europe Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 320. Europe Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 321. Germany Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 322. Germany Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 323. Germany Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 324. Germany Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 325. France Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 326. France Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 327. France Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 328. France Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 329. Italy Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 330. Italy Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 331. Italy Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 332. Italy Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 333. United Kingdom Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 334. United Kingdom Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 335. United Kingdom Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 336. United Kingdom Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 337. Netherlands Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 338. Netherlands Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 339. Netherlands Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 340. Netherlands Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 341. Rest of Europe Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 342. Rest of Europe Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 343. Rest of Europe Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 344. Rest of Europe Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 345. MEA Neuromodulation Devices, by Country USD Million (2025-2030)
  • Table 346. MEA Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 347. MEA Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 348. MEA Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 349. MEA Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 350. Middle East Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 351. Middle East Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 352. Middle East Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 353. Middle East Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 354. Africa Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 355. Africa Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 356. Africa Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 357. Africa Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 358. North America Neuromodulation Devices, by Country USD Million (2025-2030)
  • Table 359. North America Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 360. North America Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 361. North America Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 362. North America Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 363. United States Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 364. United States Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 365. United States Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 366. United States Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 367. Canada Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 368. Canada Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 369. Canada Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 370. Canada Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 371. Mexico Neuromodulation Devices, by Type USD Million (2025-2030)
  • Table 372. Mexico Neuromodulation Devices, by Application USD Million (2025-2030)
  • Table 373. Mexico Neuromodulation Devices, by End Users USD Million (2025-2030)
  • Table 374. Mexico Neuromodulation Devices, by Bio Material USD Million (2025-2030)
  • Table 375. Neuromodulation Devices Sales: by Type(K Units)
  • Table 376. Neuromodulation Devices Sales Internal Neuromodulation , by Region K Units (2025-2030)
  • Table 377. Neuromodulation Devices Sales External Neuromodulation , by Region K Units (2025-2030)
  • Table 378. Neuromodulation Devices Sales: by Application(K Units)
  • Table 379. Neuromodulation Devices Sales Depression , by Region K Units (2025-2030)
  • Table 380. Neuromodulation Devices Sales Parkinsons Disease , by Region K Units (2025-2030)
  • Table 381. Neuromodulation Devices Sales Tremor , by Region K Units (2025-2030)
  • Table 382. Neuromodulation Devices Sales Others , by Region K Units (2025-2030)
  • Table 383. Neuromodulation Devices Sales: by End Users(K Units)
  • Table 384. Neuromodulation Devices Sales Hospitals , by Region K Units (2025-2030)
  • Table 385. Neuromodulation Devices Sales Clinics , by Region K Units (2025-2030)
  • Table 386. Neuromodulation Devices Sales Home healthcare , by Region K Units (2025-2030)
  • Table 387. South America Neuromodulation Devices Sales, by Country K Units (2025-2030)
  • Table 388. South America Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 389. South America Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 390. South America Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 391. South America Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 392. Brazil Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 393. Brazil Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 394. Brazil Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 395. Brazil Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 396. Argentina Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 397. Argentina Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 398. Argentina Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 399. Argentina Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 400. Rest of South America Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 401. Rest of South America Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 402. Rest of South America Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 403. Rest of South America Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 404. Asia Pacific Neuromodulation Devices Sales, by Country K Units (2025-2030)
  • Table 405. Asia Pacific Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 406. Asia Pacific Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 407. Asia Pacific Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 408. Asia Pacific Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 409. China Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 410. China Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 411. China Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 412. China Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 413. Japan Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 414. Japan Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 415. Japan Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 416. Japan Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 417. India Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 418. India Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 419. India Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 420. India Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 421. South Korea Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 422. South Korea Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 423. South Korea Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 424. South Korea Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 425. Taiwan Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 426. Taiwan Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 427. Taiwan Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 428. Taiwan Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 429. Australia Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 430. Australia Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 431. Australia Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 432. Australia Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 433. Rest of Asia-Pacific Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 434. Rest of Asia-Pacific Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 435. Rest of Asia-Pacific Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 436. Rest of Asia-Pacific Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 437. Europe Neuromodulation Devices Sales, by Country K Units (2025-2030)
  • Table 438. Europe Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 439. Europe Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 440. Europe Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 441. Europe Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 442. Germany Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 443. Germany Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 444. Germany Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 445. Germany Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 446. France Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 447. France Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 448. France Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 449. France Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 450. Italy Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 451. Italy Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 452. Italy Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 453. Italy Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 454. United Kingdom Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 455. United Kingdom Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 456. United Kingdom Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 457. United Kingdom Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 458. Netherlands Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 459. Netherlands Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 460. Netherlands Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 461. Netherlands Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 462. Rest of Europe Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 463. Rest of Europe Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 464. Rest of Europe Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 465. Rest of Europe Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 466. MEA Neuromodulation Devices Sales, by Country K Units (2025-2030)
  • Table 467. MEA Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 468. MEA Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 469. MEA Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 470. MEA Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 471. Middle East Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 472. Middle East Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 473. Middle East Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 474. Middle East Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 475. Africa Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 476. Africa Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 477. Africa Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 478. Africa Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 479. North America Neuromodulation Devices Sales, by Country K Units (2025-2030)
  • Table 480. North America Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 481. North America Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 482. North America Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 483. North America Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 484. United States Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 485. United States Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 486. United States Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 487. United States Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 488. Canada Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 489. Canada Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 490. Canada Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 491. Canada Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 492. Mexico Neuromodulation Devices Sales, by Type K Units (2025-2030)
  • Table 493. Mexico Neuromodulation Devices Sales, by Application K Units (2025-2030)
  • Table 494. Mexico Neuromodulation Devices Sales, by End Users K Units (2025-2030)
  • Table 495. Mexico Neuromodulation Devices Sales, by Bio Material K Units (2025-2030)
  • Table 496. Neuromodulation Devices: by Type(USD/Units)
  • Table 497. Research Programs/Design for This Report
  • Table 498. Key Data Information from Secondary Sources
  • Table 499. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Europe Neuromodulation Devices: by Type USD Million (2018-2023)
  • Figure 5. Europe Neuromodulation Devices: by Application USD Million (2018-2023)
  • Figure 6. Europe Neuromodulation Devices: by End Users USD Million (2018-2023)
  • Figure 7. South America Neuromodulation Devices Share (%), by Country
  • Figure 8. Asia Pacific Neuromodulation Devices Share (%), by Country
  • Figure 9. Europe Neuromodulation Devices Share (%), by Country
  • Figure 10. MEA Neuromodulation Devices Share (%), by Country
  • Figure 11. North America Neuromodulation Devices Share (%), by Country
  • Figure 12. Europe Neuromodulation Devices: by Type K Units (2018-2023)
  • Figure 13. Europe Neuromodulation Devices: by Application K Units (2018-2023)
  • Figure 14. Europe Neuromodulation Devices: by End Users K Units (2018-2023)
  • Figure 15. South America Neuromodulation Devices Share (%), by Country
  • Figure 16. Asia Pacific Neuromodulation Devices Share (%), by Country
  • Figure 17. Europe Neuromodulation Devices Share (%), by Country
  • Figure 18. MEA Neuromodulation Devices Share (%), by Country
  • Figure 19. North America Neuromodulation Devices Share (%), by Country
  • Figure 20. Europe Neuromodulation Devices: by Type USD/Units (2018-2023)
  • Figure 21. Europe Neuromodulation Devices share by Players 2023 (%)
  • Figure 22. Europe Neuromodulation Devices share by Players (Top 3) 2023(%)
  • Figure 23. Europe Neuromodulation Devices share by Players (Top 5) 2023(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Medical, Inc. (United States.) Revenue, Net Income and Gross profit
  • Figure 26. Medical, Inc. (United States.) Revenue: by Geography 2023
  • Figure 27. LivaNova PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 28. LivaNova PLC (United Kingdom) Revenue: by Geography 2023
  • Figure 29. Boston Scientific Corporation (United States), Revenue, Net Income and Gross profit
  • Figure 30. Boston Scientific Corporation (United States), Revenue: by Geography 2023
  • Figure 31. Aleva Neurotherapeutics SA (United States) Revenue, Net Income and Gross profit
  • Figure 32. Aleva Neurotherapeutics SA (United States) Revenue: by Geography 2023
  • Figure 33. Bioness Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Bioness Inc. (United States) Revenue: by Geography 2023
  • Figure 35. EnteroMedics Inc (United States) Revenue, Net Income and Gross profit
  • Figure 36. EnteroMedics Inc (United States) Revenue: by Geography 2023
  • Figure 37. Nevro Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 38. Nevro Corporation (United States) Revenue: by Geography 2023
  • Figure 39. NeuroPace Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. NeuroPace Inc. (United States) Revenue: by Geography 2023
  • Figure 41. Synapse Biomedical, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Synapse Biomedical, Inc. (United States) Revenue: by Geography 2023
  • Figure 43. Neurosigma, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 44. Neurosigma, Inc. (United States) Revenue: by Geography 2023
  • Figure 45. Europe Neuromodulation Devices: by Type USD Million (2025-2030)
  • Figure 46. Europe Neuromodulation Devices: by Application USD Million (2025-2030)
  • Figure 47. Europe Neuromodulation Devices: by End Users USD Million (2025-2030)
  • Figure 48. South America Neuromodulation Devices Share (%), by Country
  • Figure 49. Asia Pacific Neuromodulation Devices Share (%), by Country
  • Figure 50. Europe Neuromodulation Devices Share (%), by Country
  • Figure 51. MEA Neuromodulation Devices Share (%), by Country
  • Figure 52. North America Neuromodulation Devices Share (%), by Country
  • Figure 53. Europe Neuromodulation Devices: by Type K Units (2025-2030)
  • Figure 54. Europe Neuromodulation Devices: by Application K Units (2025-2030)
  • Figure 55. Europe Neuromodulation Devices: by End Users K Units (2025-2030)
  • Figure 56. South America Neuromodulation Devices Share (%), by Country
  • Figure 57. Asia Pacific Neuromodulation Devices Share (%), by Country
  • Figure 58. Europe Neuromodulation Devices Share (%), by Country
  • Figure 59. MEA Neuromodulation Devices Share (%), by Country
  • Figure 60. North America Neuromodulation Devices Share (%), by Country
  • Figure 61. Europe Neuromodulation Devices: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Medical, Inc. (United States.)
  • LivaNova PLC (United Kingdom)
  • Boston Scientific Corporation (United States),
  • Aleva Neurotherapeutics SA (United States)
  • Bioness Inc. (United States)
  • EnteroMedics Inc (United States)
  • Nevro Corporation (United States)
  • NeuroPace Inc. (United States)
  • Synapse Biomedical, Inc. (United States)
  • Neurosigma, Inc. (United States)
Additional players considered in the study are as follows:
Neuronetics, Inc. (United States) , Cyberonics, Inc. (United States) , BioControl Medical (Israel), , Accellent (United States) , DynaMD (United States) , Soterix Medical, Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 227 Pages 76 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Medical, Inc. (United States.), LivaNova PLC (United Kingdom), Boston Scientific Corporation (United States),, Aleva Neurotherapeutics SA (United States), Bioness Inc. (United States), EnteroMedics Inc (United States), Nevro Corporation (United States), NeuroPace Inc. (United States), Synapse Biomedical, Inc. (United States) and Neurosigma, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Advancement of Neuromodulation Devices" is seen as one of major influencing trends for Neuromodulation Devices Market during projected period 2023-2030.
The Neuromodulation Devices market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Neuromodulation Devices Global Report?